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Abstract
 
Aims
 
Type 2 diabetes mellitus and microalbuminuria are important risk factors for cardiovascular disease (CVD).
Whether these two complications are important and independent risk factors for future CVD events in a high-risk
population with clinically manifest vascular disease is unknown. The objectives of this study were to examine the impact
of Type 2 diabetes and microalbuminuria on future CVD events.
 
Methods
 
Patients with clinically manifest vascular disease (coronary, cerebral and peripheral vascular disease) from the
Second Manifestation of Arterial disease study were followed up for 4 years. Data obtained from 1996–2006 were
analysed. At baseline, there were 804 patients with Type 2 diabetes mellitus (mean age 60 years) and 2983 patients without.
Incident CVD (
 
n
 
 = 458) was defined as hospital-verified myocardial infarction, stroke, vascular death and the composite
of these vascular events.
 
Results
 
Both Type 2 diabetes [hazard ratio (HR) 1.42, 95% confidence interval (CI) 1.16, 1.75] and microalbuminuria
(HR 1.86, 95% CI 1.49, 2.33) increased the risk of new cardiovascular events in univariate analyses. From multivariable
models, presence of diabetes remained significantly and independently related to incident CVD (HR 1.42, 95% CI 1.11,
1.80). Presence of microalbuminuria also remained significantly independently related to incident CVD (HR 1.38, 95%
CI 1.07, 1.77). In diabetes-stratified analyses, the effect of microalbuminuria on CVD risk was observed only in patients
with diabetes. In microalbuminuria-stratified analyses, the significant and independent effect of diabetes on CVD risk was
shown only in the non-microalbuminuric group.
 
Conclusions
 
In this high-risk population, both microalbuminuria and Type 2 diabetes are important and independent
risk factors for future CVD.
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Introduction
 
Having Type 2 diabetes is an important risk factor for the
development of cardiovascular disease (CVD), with relative
risks between 2 and 4 compared with those without diabetes
[1–6]. Microalbuminuria is, on the other hand, one of the most
important contributors to the increased CVD risk in patients
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with Type 2 diabetes compared with individuals without
diabetes [7–10]. In a high-risk population with clinically manifest
vascular disease, Type 2 diabetes and microalbuminuria could
still be important risk factors for future CVD events. However,
the role of both these factors has not been studied in high-risk
populations. Could both diabetes and microalbuminuria be
equally important in the aetiology of future CVD? It is thought
that the three conditions diabetes, microalbuminuria and
CVD could all share common antecedents or underlying risk
factors in the causal pathway, in the so-called common soil
hypothesis [11].
Whether the effects of Type 2 diabetes and microalbuminuria
are independent of each other in their relation with future CVD
events remains unclear. Hence, our main aim was to examine
whether the impact of Type 2 diabetes on the risk of future
CVD is independent from that of microalbuminuria and vice
versa in a population with clinically manifest vascular disease.
 
Methods
 
The Second Manifestations of ARTerial disease (SMART)
study is an ongoing prospective, single-centre cohort study in
patients with clinically manifest vascular disease or cardiovascular
risk factors. The main inclusion criteria are coronary, cerebral
or peripheral artery disease, renal artery stenosis, aneurysm of
the abdominal aorta (AAA), or risk factors for atherosclerosis
comprising dyslipidaemia, diabetes mellitus (Types 1 and 2)
and/or hypertension. Excluded are patients with a terminal
malignancy, those not able to live independently (Rankin scale
> 3) or not sufficiently fluent in Dutch, and those referred back
to the referring specialist immediately after one visit.
All participants aged 18–80 years referred to the University
Medical Centre Utrecht (UMC Utrecht), the Netherlands, since
1996 have been included. After referral, subjects underwent
vascular screening including a questionnaire, blood chemistry
and ultrasonography. Eligible patients received written and oral
information about the goals and methodology of the study from
qualified research nurses or doctors at their first or second visit
to the hospital and all patients were asked for written informed
consent. The study was approved by the medical ethics committee
of the UMC Utrecht. The rationale and design of the SMART
study have been described in detail elsewhere [12].
Recruitment to the SMART study is ongoing and approxim-
ately 800 patients are enrolled annually. On 1 March 2006,
5822 patients with at least 6 months’ follow-up data had been
recruited. We restricted the population to those with clinically
manifest vascular disease only (excluding 1947 patients who
did not have a history of CVD); thus 3875 patients were included.
Those patients with diagnosed Type 1 diabetes mellitus
(
 
n
 
 = 38) were excluded, leaving 3837 patients. Type 2 diabetes
was diagnosed by a physician, or defined as a fasting plasma
glucose 
 
≥
 
 7.0 mmol/l or self-reported use of oral glucose-lowering
drugs or insulin.
Microalbuminuria was defined as a urinary albumin:creatinine
ratio between 2.5 and 25 mg/mmol (men) or between 3.5 and
25 mg/mmol (women) [13]. The glomerular filtration rate
(GFR) was calculated using the Cockcroft–Gault formula;
in ml/min [(140 – age) 
 
×
 
 body weight/(serum creatinine 
 
×
 
 72)
(
 
×
 
 0.85 if female)] [14] and expressed per 1.73 m
 
2
 
 body surface
area.
 
Follow-up
 
Patients were asked biannually to complete a questionnaire on
hospital admissions and out-patient clinic visits. The follow-up
was complete for 98.1%. Events of interest for this study were
CVD, comprising ischaemic heart disease, myocardial infarction,
ischaemic stroke, vascular death and the composite of these
vascular events. When a possible event was recorded by the
participant, hospital discharge letters and results of relevant
laboratory and radiology examinations were collected. For each
event, written standard operating procedures were followed
to classify each event accordingly. Based on this information,
all events were audited independently by three members of the
SMART study Endpoint Committee, comprising physicians from
different departments. In case of disagreement, the opinion of other
members of the Endpoint Committee was sought and final adjudi-
cation was based on the majority of the classifications obtained.
 
Statistical analyses
 
Absolute risks were calculated by dividing the number of CVD
events by person-years. Cox proportional hazards analyses
were performed to estimate relative risks [hazard ratios (HR)
and 95% confidence intervals (CI)] for the association between
Type 2 diabetes and CVD and microalbuminuria and CVD. If
a patient had multiple events, the first was used in the analyses.
Multivariate Cox proportional hazards analyses were carried
out. Kaplan–Meier survival curves were drawn to illustrate the
effects of diabetes, microalbuminuria and the combination of
the two on CVD during the follow-up period. The Kaplan–Meier
curves were reversed by calculating one minus survival. The
proportional hazards assumption was found not to be violated
by examining the parallel Kaplan–Meier curves as well as using
the Schoenfeld test (
 
P
 
 = 0.6 for microalbuminuria and 
 
P
 
 = 0.9
for diabetes) [15]. Likelihood ratio tests were used additionally
to test for an interaction between diabetes and microalbuminuria
(comparing a model with diabetes and microalbuminuria with a
model with diabetes, microalbuminuria and the interaction
term). Adjustments were made for confounders such as age,
sex, renal function (using the estimated GFR by Cockcroft–Gault
formula), systolic blood pressure, smoking, fasting triglycerides,
body mass index (BMI) and the use of angiotensin-converting
enzyme (ACE) inhibitors or angiotensin II receptor antagonists.
We have adjusted for all potential confounding variables which
are known to be related to the determinants (Type 2 diabetes or
microalbuminuria), but also to the study outcome (CVD). From
each risk factor group, one factor was chosen, e.g. fasting
triglycerides was chosen from lipids and lipoproteins, BMI was
chosen from obesity measures. The analyses were also carried out
using diabetes-stratified analyses, microalbuminuria-stratified
analyses, and using albumin:creatinine ratio as a continuous
variable instead of using a cut-off for microalbuminuria. The
statistical packages STATA (STATA 7.0; Stata Corp., College
Station, TX, USA) and SPSS (SPSS 11.0; SPSS Inc., Chicago, IL,
USA) were used to perform all statistical analyses. A 
 
P
 
-value
< 0.05 was considered to be statistically significant.
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Results
 
An overview of the baseline characteristics of the SMART
population by diabetes status and by microalbuminuria status
is shown in Table 1. There were 804 patients with Type 2
diabetes and 2983 patients without, 640 patients with micro-
albuminuria and 2956 without. There were 50 missing values
for diabetes and 241 missing values for microalbuminuria.
Mean age was 60 years and 75% were male. There was a
significant difference in the age (62 vs. 59 years, 
 
P
 
 < 0.0001),
but not sex (
 
P
 
 = 0.9) between those with and without Type 2
diabetes. There were significant differences in the age and sex
distribution between those with and without microalbuminuria
(63 vs. 59 years, 
 
P
 
 < 0.0001 and 79 vs. 74% men, 
 
P
 
 = 0.005).
As expected, those with diabetes had higher baseline fasting
plasma glucose levels and were more obese as well as more
hypertensive than those without diabetes. In addition, a higher
proportion of those with diabetes had microalbuminuria
(defined as an albumin:creatinine ratio between 2.5 and
25 mg/mmol in men or 3.5 and 25 mg/mmol in women), with
26 vs. 16% in those without diabetes. The prevalence of Type
2 diabetes in the microalbuminuric population was 30% and
19% in those without microalbuminuria. A considerable
proportion of the patients had concomitant cerebrovascular,
peripheral arterial disease, coronary artery disease or AAA
(Table 2).
During the follow-up period [3.8 
 
±
 
 2.6 years (mean 
 
±
 
 
 
SD
 
)],
458 patients experienced an incident CVD event (121 in the
diabetic population, 332 in those without diabetes, 102 in
those with microalbuminuria and 318 in those without micro-
albuminuria). As shown in Fig. 1, the overall absolute risk of
CVD was lowest in the non-diabetic and non-microalbuminuric
populations and increased significantly for those with micro-
albuminuria. Those with both Type 2 diabetes and micro-
albuminuria had an absolute CVD risk of 52/1.000 person-years
(95% CI 37, 74). The microalbuminuria effect was no greater
in those with Type 2 diabetes than in those without, since the
last two bars of Fig. 1 were similar.
Both Type 2 diabetes (HR 1.42, 95% CI 1.16, 1.75) and
microalbuminuria (HR 1.86, 95% CI 1.49, 2.33) increased
the risk of new cardiovascular events in univariate analyses
(Table 3). There was no significant interaction between diabetes
and microalbuminuria (likelihood ratio test 
 
P
 
 = 0.10, 
 
β
 
coefficient 
 
−
 
0.41, 95% CI 
 
−
 
0.90, 0.08). To explore whether
the presence of Type 2 diabetes or microalbuminuria were
independent of each other in relation to CVD, both variables
were entered simultaneously into a multivariable model.
These analyses showed that both the presence of diabetes
and microalbuminuria were significantly and independently
related to incident CVD. Analyses were carried out to adjust
for cardiovascular risk factors, estimated GFR, systolic blood
pressure, smoking, fasting triglycerides and BMI, and use of
blood pressure-lowering medication such as ACE inhibitors
and angiotensin II antagonists, but these also showed that both
diabetes and microalbuminuria are important risk factors for
the development of CVD (Table 3, model 5–7).
Table 1 Baseline phenotypic characteristics of the SMART cohort by diabetes and microalbuminuria status
Diabetes 
(n = 804) 
Mean ± SD
Without diabetes 
(n = 2983) 
Mean ± SD
Microalbuminuria 
(n = 640) 
Mean ± SD
Without 
microalbuminuria
(n = 2956) 
Mean ± SD
Age at baseline (years)  62 ± 9  59 ± 11  64 ± 10  59 ± 10
Duration of diabetes (years) 6.3 ± 7.2 — — —
Fasting plasma glucose (mmol/l) 8.9 ± 2.8 5.6 ± 0.6 6.6 ± 2.2 6.2 ± 1.9
Systolic BP (mmHg)  147 ± 21  140 ± 19  149 ± 22  140 ± 19
Diastolic BP (mmHg)  81 ± 10  79 ± 10  82 ± 11  79 ± 10
Pulse pressure  67 ± 17  60 ± 15  67 ± 17  61 ± 16
Cholesterol (mmol/l) 5.1 ± 1.3 5.2 ± 1.2 5.2 ± 1.2 5.2 ± 1.2
LDL-cholesterol (mmol/l) 3.0 ± 1.0 3.2 ± 1.0 3.1 ± 1.0 3.2 ± 1.0
HDL-cholesterol (mmol/l) 1.1 ± 0.3 1.3 ± 0.4 1.2 ± 0.4 1.2 ± 0.4
Fasting triglycerides (mmol/l)* 1.9 (1.3, 2.7) 1.5 (1.1, 2.1) 1.6 (1.1, 2.3) 1.5 (1.1, 2.2)
Non-HDL-cholesterol (mmol/l) 4.0 ± 1.3 4.0 ± 1.2 3.9 ± 1.2 4.0 ± 1.2
Weight (kg) (men/women)  87 ± 14  83 ± 12  83 ± 13  84 ± 13
 79 ± 15  71 ± 13  73 ± 16  72 ± 13
Waist–hip ratio (men/women) 0.96 ± 0.07/
0.88 ± 0.06
0.93 ± 0.06/
0.84 ± 0.07
0.95 ± 0.07/
0.85 ± 0.06
0.94 ± 0.06/
0.84 ± 0.07
Body mass index (kg/m2) (men/women) 27.9 ± 3.9/
29.1 ± 5.2
26.4 ± 3.4/
26.1 ± 4.5
26.7 ± 3.8/
27.2 ± 5.6
26.7 ± 3.5/
26.6 ± 4.6
Glomerular filtration rate, Cockcroft–
Gault (ml/min per 1.73 m2)
77.5 ± 25.1 76.4 ± 21.6 70.6 ± 24.1 78.3 ± 21.1
Albumin creatinine ratio (mg/mmol)* 1.7 (1.0, 3.9) 1.2 (0.8, 2.1) 4.7 (3.3, 8.5) 1.1 (0.7, 1.6)
*Median (IQR).
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Kaplan–Meier curves (Fig. 2) illustrate the effects of Type 2
diabetes and microalbuminuria on CVD across the whole
follow-up period. Throughout the whole follow-up period, the
presence of both Type 2 diabetes and microalbuminuria at
baseline increased the risk of future CVD. As in Fig. 1, Fig. 2
also showed that microalbuminuria increased the risk of
developing CVD across the whole period equally in those with
and without Type 2 diabetes.
Further stratified analyses were carried out by Type 2
diabetes (Table 4a) and microalbuminuria (Table 4b). These
analyses showed that the presence of microalbuminuria was
significantly related to an increased risk of CVD in those
patients without diabetes, but not in those with Type 2 diabetes.
Similarly, the effect of microalbuminuria on CVD was apparent
only in those without diabetes.
Final analyses were carried out (data not shown) using
albumin:creatinine ratio as a continuous variable, instead of
microalbuminuria as a categorical variable. The final model
with Type 2 diabetes, albumin:creatinine ratio per 10 mg/
mmol increase, age, sex, renal function, systolic blood pressure,
smoking, fasting triglycerides, BMI, ACE inhibitors and
Table 2 Baseline treatment and clinical characteristics of the SMART cohort by diabetes and microalbuminuria status
Diabetes
% (n)
Without 
diabetes 
% (n)
Microalbuminuria
% (n)
Without 
microalbuminuria
% (n)
Men 75 (604) 75 (2233) 79 (508) 74 (2189)
Ever smoked 80 (641) 82 (2452) 84 (536) 81 (2392)
Ever drank alcohol 75 (595) 82 (2444) 79 (502) 81 (2393)
Hypertension* 85 (681) 72 (2150) 86 (550) 72 (2138)
BP-lowering drugs 54 (430) 38 (1144) 50 (317) 39 (1159)
ACE inhibitors and ATA II use 38 (308) 24 (711) 33 (213) 26 (757)
Lipid-lowering drugs 53 (418) 47 (1408) 48 (305) 48 (1416)
Microalbuminuria 26 (191) 16 (438) — —
Diabetes mellitus — — 30 (191) 19 (557)
Cerebrovascular disease 19 (155) 22 (655) 23 (147) 21 (626)
Peripheral arterial disease 22 (175) 18 (546) 22 (138) 19 (560)
Coronary artery disease 35 (280) 42 (1242) 30 (194) 42 (1249)
AAA 5 (40) 8 (225) 9 (59) 6 (187)
ATA II, Angiotensin II antagonists.
*> 140/90 mmHg or on BP-lowering drugs.
FIGURE 1 Crude absolute risk of cardiovascular disease per 
1000 person-years.
Table 3 Hazard ratio for future CVD by baseline Type 2 diabetes status 
or microalbuminuria* status
HR 
(95% CI)
Type 2 diabetes 
yes vs. no
Microalbuminuria
yes vs. no
Model 1 1.42 (1.16, 1.75) 1.86 (1.49, 2.33)
Model 2 1.27 (1.03, 1.56) 1.46 (1.16, 1.84)
Model 3 1.34 (1.07, 1.67) 1.85 (1.48, 2.32)
Model 4 1.24 (1.00, 1.55) 1.48 (1.18, 1.86)
Model 5 1.32 (1.06, 1.65) 1.38 (1.09, 1.74)
Model 6 1.44 (1.13, 1.83) 1.38 (1.07, 1.77)
Model 7 1.42 (1.11, 1.80) 1.38 (1.07, 1.77)
*Defined by ACR 2.5–25 mg/mmol in men and 3.5–25 mg/mmol 
in women.
Model 1: Univariate analyses. Model with diabetes related with 
CVD. Model with microalbuminuria.
Model 2: Model with diabetes, adjusted for age, sex. Model with 
microalbuminuria, adjusted for age and sex.
Model 3: Model with diabetes, adjusted for microalbuminuria. 
Model with microalbuminuria, adjusted for diabetes.
Model 4: Model with diabetes, adjusted for microalbuminuria, 
age and sex. Model with microalbuminuria, adjusted for 
diabetes, age and sex.
Model 5: Model 4 + renal function.
Model 6: Model 5 + systolic blood pressure, smoking, fasting 
triglycerides and body mass index.
Model 7: Model 6 + ACE inhibitors and angiotensin II 
antagonists.
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angiotensin II antagonists resulted in HRs for Type 2 diabetes
and albumin:creatinine ratio of, respectively, 1.39 (95% CI
1.09, 1.77) and 1.06 (95% CI 1.02, 1.09). These results
confirm that Type 2 diabetes and albuminuria are important
risk factors for future CVD in patients already at very high risk
and that, although they are interrelated, the effects seem
independent of each other.
Discussion
In this population with manifest vascular disease it was found
that both microalbuminuria and Type 2 diabetes are important
and independent risk factors for future CVD. These patients
are already at high risk because of their history of CVD, but
nevertheless, baseline presence of Type 2 diabetes and micro-
albuminuria add considerably to the risk of future CVD. An
attractive hypothesis is that all three diseases—diabetes,
microalbuminuria and CVD—underlie the so-called ‘common
soil hypothesis’ [11] and share common antecedents. A main
limitation of this study is that we could not investigate this
hypothesis further since we do not have data on the period
before the onset of microalbuminuria or Type 2 diabetes. All
that is known is that the mean duration of diabetes was
approximately 8 years in this study, and the onset of CVD is
dependent on duration of diabetes as well as microalbuminuria.
We also cannot account for post-baseline development of
microalbuminuria, because both Type 2 diabetes and micro-
albuminuria were assessed at baseline only. On the basis of the
data on baseline microalbuminuria and Type 2 diabetes, it can
be said, however, that the early presence of both of these
abnormalities is related to the development of future CVD.
What could be the underlying pathophysiological mechanism
for diabetes and microalbuminuria being independently related
to future CVD [16,17]? Several mechanisms have been sug-
gested, such as endothelial dysfunction, low-grade inflamma-
tion and oxidative stress, but the nature of the link between
diabetes and/or microalbuminuria and cardiovascular risk
remains poorly understood. Endothelial dysfunction seems an
attractive link and is thought to play an important role not
only in the initiation of atherosclerosis, but also in its pro-
gression and clinical sequelae. It is not clear to what extent
endothelial dysfunction is caused by hyperglycaemia. Type 2
diabetes typically occurs in the context of a cluster of risk
factors, notably obesity, hypertension, high triglyceride levels,
FIGURE 2  Kaplan–Meier survival function for cardiovascular disease.
Table 4 (a) Stratified analyses by diabetes status
HR (95% CI) Type 2 diabetes No diabetes
Model 1 1.39 (0.91, 2.11) 2.11 (1.62, 2.75)
Model 2 1.31 (0.86, 1.99) 1.54 (1.17, 2.03)
Model 3 1.42 (1.07, 1.87)
Model 4 1.38 (1.02, 1.88)
Model 5 1.38 (1.02, 1.88)
*Defined by ACR 2.5–25 mg/mmol in men and 3.5–25 mg/mmol 
in women.
Model 1: Univariate analyses. The model with microalbuminuria 
alone.
Model 2: Adjusted for age and sex.
Model 3: Model 2 + renal function.
Model 4: Model 3 + systolic blood pressure, smoking, fasting 
triglycerides and body mass index.
Model 5: Model 4 + ACE inhibitors and angiotensin II 
antagonists.
(b) Stratified analyses by microalbuminuria status
HR (95% CI) Microalbuminuria No microalbuminuria
Model 1 1.00 (0.65, 1.52) 1.50 (1.17, 1.94)
Model 2 1.07 (0.70, 1.65) 1.32 (1.02, 1.71)
Model 3 1.41 (1.09, 1.82)
Model 4 1.52 (1.15, 2.02)
Model 5 1.48 (1.12, 1.96)
Model 1: Univariate analyses. The model with diabetes alone.
Model 2: Adjusted for age and sex.
Model 3: Model 2 + renal function.
Model 4: Model 3 + systolic blood pressure, smoking, fasting 
triglycerides and body mass index.
Model 5: Model 4 + ACE inhibitors and angiotensin II 
antagonists.
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low high-density lipoprotein-cholesterol levels, abnormal
low-density lipoprotein composition, hyperinsulinaemia,
insulin resistance and low-grade inflammation, in addition to
microalbuminuria. All these factors may impair endothelial
function. Whether endothelial dysfunction induced by diabetes
is independent of that induced by microalbuminuria remains
to be established. Microalbuminuria is a strong and independent
indicator of increased cardiovascular risk. In addition, it has
also been shown that microalbuminuria is associated with
endothelial dysfunction in the absence of diabetes [18]
Speculating further, diabetes could also be associated with
endothelial dysfunction, in the absence of microalbuminuria.
This is supported by the finding that microalbuminuria occurs
in the absence of severe endothelial dysfunction [19]. This is in
line with our findings, that the effect of Type 2 diabetes on
CVD was shown only in those without microalbuminuria and
the effect of microalbuminuria on CVD was shown only in
those without diabetes.
Our analyses have shown that microalbuminuria is not
related to CVD in patients with Type 2 diabetes. This finding
conflicts with results from several studies, which found that
the presence of microalbuminuria in patients with diabetes
does increase CVD risk [7–10], as in patients without diabetes.
Our finding may be due to the high baseline risk of our
patients, with at least 40% having a history of coronary heart
disease (CHD), precluding further risk increase by presence of
microalbuminuria, particularly in those with diabetes mellitus.
Recently, proteinuria has been shown to be an independent
predictor of CVD mortality in patients with Type 2 diabetes
mellitus in a 18-year Finnish follow-up study, after adjusting
for the metabolic syndrome, with a HR of 1.6 (95% CI 1.0,
2.6) [20]. Unfortunately, proteinuria was defined differently as
a urinary protein concentration ≥ 0.1 g/l and the effect of Type
2 diabetes itself on cardiovascular mortality was not assessed
in this study, but the positive independent relationship
between proteinuria and CVD mortality in those with diabetes
parallels our results for microalbuminuria.
Previous studies have examined the role of diabetes as an
important risk factor for CVD, but not in such a high-risk
population as our SMART population, and not after adjustment
for microalbuminuria. Much higher relative risks of 3–9 were
found in these relatively lower-risk populations [3–5] without
adjustment for microalbuminuria. The association between
microalbuminuria and cardiovascular mortality in patients
with Type 2 diabetes has been studied extensively. A
meta-analysis has demonstrated a twofold increased risk of
total and cardiovascular morbidity and mortality associated
with microalbuminuria [21]. Microalbuminuria also predicts
incident CVD in the general population, and many studies
have adjusted for diabetes duration or diabetes itself
[9,10,22,23]. A Danish study has demonstrated a significant
relationship between very low levels of urinary albumin
excretion (> 4.8 μg/min) and incident CHD and death, which
was also independent of diabetes with a relative risk of 2.0
(95% CI 1.3, 2.9) [24].
Previously, reduced renal creatinine clearance or chronic
kidney disease have been shown to be independent predictors
of CVD [25–27]. Therefore, we have adjusted the association
between microalbuminuria and CVD for renal creatinine clearance
and found no confounding influence on the reported association.
In summary, both Type 2 diabetes and microalbuminuria
are important independent risk factors for future CVD. It is
important to target both Type 2 diabetes and microalbuminuria
(or albuminuria in general) as early as possible in order to
prevent CVD. In addition, the effect of microalbuminuria on
CVD is apparent in those without diabetes, but not in those
with Type 2 diabetes. The effect of Type 2 diabetes on CVD
risk is apparent in those without microalbuminuria, but not in
those with microalbuminuria.
Competing interests
None to declare.
Acknowledgements
We thank all study participants and staff who contributed to
the SMART study. The SMART study is funded by separate
grants of Dutch scientific research organizations (N.W.O.,
ZON-MW).
References
1 Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk
factors, and 12-yr cardiovascular mortality for men screened in the
Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:
434–444.
2 Howard BV, Cowan LD, Go O, Welty TK, Robbins DC, Lee ET et al.
Adverse effects of diabetes on multiple cardiovascular disease risk
factors in women. The Strong Heart Study. Diabetes Care 1998; 21:
1258–1265.
3 Lotufo PA, Gaziano JM, Chae CU et al. Diabetes and all-cause and
coronary heart disease mortality among US male physicians. Arch
Intern Med 2001; 161: 242–247.
4 Cho E, Rimm EB, Stampfer MJ, Willett WC, Hu FB. The impact of
diabetes mellitus and prior myocardial infarction on mortality from
all causes and from coronary heart disease in men. J Am Coll Cardiol
2002; 40: 954–960.
5 Hu FB, Stampfer MJ, Solomon CG et al. The impact of diabetes mellitus
on mortality from all causes and coronary heart disease in women:
20 years of follow-up. Arch Intern Med 2001; 161: 1717–1723.
6 Becker A, Bos G, de Vegt F et al. Cardiovascular events in Type 2
diabetes: comparison with nondiabetic individuals without and with
prior cardiovascular disease: 10-year follow-up of the Hoorn Study.
Eur Heart J 2003; 24: 1406–1413.
7 Mattock MB, Barnes DJ, Viberti G et al. Microalbuminuria and
coronary heart disease in NIDDM: an incidence study. Diabetes
1998; 47: 1786–1792.
8 Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular
disease mortality associated with microalbuminuria and gross
proteinuria in persons with older-onset diabetes mellitus. Arch Intern
Med 2000; 160: 1093–1100.
9 Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardio-
vascular events, death, and heart failure in diabetic and nondiabetic
individuals. JAMA 2001; 286: 421–426.
Original article DIABETICMedicine
© 2008 The Authors.
Journal compilation © 2008 Diabetes UK. Diabetic Medicine, 25, 51–57 57
10 Agewall S, Wikstrand J, Ljungman S, Fagerberg B. Usefulness of
microalbuminuria in predicting cardiovascular mortality in treated
hypertensive men with and without diabetes mellitus. Risk Factor
Intervention Study Group. Am J Cardiol 1997; 80: 164–169.
11 Stern MP. Diabetes and cardiovascular disease. The ‘common soil’
hypothesis. Diabetes 1995; 44: 369–374.
12 Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y.
Second manifestations of ARTerial disease (SMART) study: rationale
and design. Eur J Epidemiol 1999; 15: 773–781.
13 Yuyun MF, Adler AI, Wareham NJ. What is the evidence that
microalbuminuria is a predictor of cardiovascular disease events?
Curr Opin Nephrol Hypertens 2005; 14: 271–276.
14 Cockcroft DW, Gault MH. Prediction of creatinine clearance from
serum creatinine. Nephron 1976; 16: 31–41.
15 Schoenfeld D. Partial residuals for the proportional hazards
regression model. Biometrika 1982; 69: 239–241.
16 Stehouwer CDA, Smulders YM. Microalbuminuria and risk for
cardiovascular disease: analysis of potential mechanisms. J Am Soc
Nephrol 2006; 17: 2106–2111.
17 Schalkwijk CG, Stehouwer CDA. Vascular complications in diabetes
mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 2005;
109: 143–159.
18 Stehouwer CD, Henry RM, Dekker JM et al. Microalbuminuria is
associated with impaired brachial artery, flow-mediated vasodilation
in elderly individuals without and with diabetes: further evidence for
a link between microalbuminuria and endothelial dysfunction—the
Hoorn Study. Kidney Int Suppl 2004; 92: S42–S44.
19 Fioretto P, Stehouwer CD, Mauer M et al. Heterogeneous nature of
microalbuminuria in NIDDM: studies of endothelial function and
renal structure. Diabetologia 1998; 41: 233–236.
20 Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria
and metabolic syndrome as predictors of cardiovascular death in
non-diabetic and Type 2 diabetic men and women. Diabetologia
2006; 49: 56–65.
21 Dinneen SF, Gerstein HC. The association of microalbuminuria
and mortality in non-insulin-dependent diabetes mellitus. A
systematic overview of the literature. Arch Intern Med 1997; 157:
1413–1418.
22 Borch-Johnsen K, Feldt RB, Strandgaard S, Schroll M, Jensen JS.
Urinary albumin excretion. An independent predictor of ischemic
heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1992–1997.
23 Yuyun MF, Khaw KT, Luben R et al. Microalbuminuria independently
predicts all-cause and cardiovascular mortality in a British population:
The European Prospective Investigation into Cancer in Norfolk (EPIC-
Norfolk) population study. Int J Epidemiol 2004; 33: 189–198.
24 Klausen K, Borch-Johnsen K, Feldt-Rasmussen B et al. Very low
levels of microalbuminuria are associated with increased risk of
coronary heart disease and death independently of renal function,
hypertension, and diabetes. Circulation 2004; 110: 32–35.
25 Weiner DE, Tighiouart H, Amin MG et al. Chronic kidney disease as
a risk factor for cardiovascular disease and all-cause mortality: a
pooled analysis of community-based studies. J Am Soc Nephrol
2004; 15: 1307–1315.
26 Manjunath G, Tighiouart H, Coresh J et al. Level of kidney function
as a risk factor for cardiovascular outcomes in the elderly. Kidney Int
2003; 63: 1121–1129.
27 Meisinger C, Doring A, Lowel H. Chronic kidney disease and risk of
incident myocardial infarction and all-cause and cardiovascular
disease mortality in middle-aged men and women from the general
population. Eur Heart J 2006; 27: 1245–1250.
